Zepbound should not be combined with other GLP-1/GIP agents, and combination anti-obesity pharmacotherapy is generally off-label requiring specialist oversight
Expanding the use of GLP-1 receptor agonists across obesity, cardiovascular disease, chronic kidney disease, MASH, and other metabolic disorders requires manufacturers to generate robust long-term clinical evidence for each therapeutic indication
If the included articles did not report SD, SD was calculated using the reported confidence interval or standard errors via the RevMan calculator
Claims also extend to a range of other benefits such as regeneration and muscle recovery, cellular energy and health, calming inflammation and more
This helps confirm the diagnosis, rule out other conditions, and ensure UFE is a safe and appropriate treatment option